While Ozempic remains popular, a new weight loss product called Wegovy is now available to Canadians. Wegovy, manufactured by Novo Nordisk, has entered the Canadian market to meet the high demand for Ozempic and provide more weight loss treatment options to Canadians. Unlike Ozempic, which is approved for multiple uses, Wegovy is specifically approved for weight loss and contains a higher dose of appetite suppressants. This drug is recommended for patients who are significantly overweight and have associated medical conditions.
This development is particularly important for the eight million Canadians who struggle with obesity and could make a significant difference in their weight loss journey. With Wegovy's entry into the pharmacy market, Canadians now have access to both popular treatment options.


news source